CSL Behring begins phase II study of COVID-19 therapy

By The Science Advisory Board staff writers

July 6, 2020 -- CSL Behring has enrolled the first patient in its phase clinical II study to assess the safety and efficacy of CSL312 (garadacimab, factor XIIa-inhibitory monoclonal antibody) to treat respiratory distress associated with COVID-19.

The multicenter, double-blind, placebo-controlled study will enroll approximately 124 adult patients with COVID-19. CSL312 will be administered intravenously in combination with standard-of-care treatments.

CSL312 inhibits the plasma protein, Factor XIIa, to prevent the molecular cascade leading to edema formation. It is also under clinical development as a once-monthly subcutaneous prophylactic treatment for attacks related to hereditary angioedema.

In addition to the study of CSL312, the company is also:

  • Working with the Coalition for Epidemic Preparedness Innovations (CEPI), and the University of Queensland on a COVID-19 vaccine
  • Working with the CoVIg-19 Plasma Alliance to develop anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin treatment
  • Developing an anti-SARS-CoV-2 plasma product for the Australian market
  • Partnering with SAB Biotherapeutics to develop a novel immunotherapy targeting COVID-19
CSL Behring, Seattle Children's to develop gene therapies
CSL Behring, a biotechnology company, and Seattle Children's Research Institute announced that the organizations have entered a strategic alliance to...

Copyright © 2020 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter